Relationship of sFas with metabolic risk factors and their clusters

Eur J Clin Invest 2010; 40 (6): 527–533

[1]  A. Tamakoshi,et al.  C-reactive protein levels and risk of mortality from cardiovascular disease in Japanese: the JACC Study. , 2009, Atherosclerosis.

[2]  C. Stefanadis,et al.  The role of oxidative stress in atherosclerosis. , 2009, Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese.

[3]  H. Yatsuya,et al.  Self-reported medical history was generally accurate among Japanese workplace population. , 2009, Journal of clinical epidemiology.

[4]  A. Tamakoshi,et al.  Soluble Fas level and cancer mortality: Findings from a nested case–control study within a large‐scale prospective study , 2008, International journal of cancer.

[5]  A. Tamakoshi,et al.  Serum total cholesterol levels and risk of mortality from stroke and coronary heart disease in Japanese: the JACC study. , 2007, Atherosclerosis.

[6]  F. Cipollone,et al.  Oxidative stress, inflammation and atherosclerotic plaque development , 2007 .

[7]  K. Yamagishi,et al.  Metabolic Syndrome and the Risk of Ischemic Heart Disease and Stroke Among Japanese Men and Women , 2007, Stroke.

[8]  A. Langer,et al.  Increased Soluble Fas Plasma Levels in Subjects at High Cardiovascular Risk: Atorvastatin on Inflammatory Markers (AIM) Study, a Substudy of ACTFAST , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[9]  J. Shaw,et al.  Metabolic syndrome—a new world‐wide definition. A Consensus Statement from the International Diabetes Federation , 2006, Diabetic medicine : a journal of the British Diabetic Association.

[10]  J. Chan,et al.  High prevalence of metabolic syndrome in Hong Kong Chinese--comparison of three diagnostic criteria. , 2005, Diabetes research and clinical practice.

[11]  A. Tamakoshi,et al.  Body Mass Index and Mortality From Cardiovascular Disease Among Japanese Men and Women: The JACC Study , 2005, Stroke.

[12]  A. Tamakoshi,et al.  Stability of Frozen Serum Levels of Insulin-like Growth Factor-I, Insulin-like Growth Factor-II, Insulin-like Growth Factor Binding Protein-3, Transforming Growth Factor β, Soluble Fas, and Superoxide Dismutase Activity for the JACC Study , 2005, Journal of epidemiology.

[13]  A. Tamakoshi,et al.  Profile of the JACC Study , 2005, Journal of epidemiology.

[14]  Morihiro Matsuda,et al.  Increased oxidative stress in obesity and its impact on metabolic syndrome. , 2004, The Journal of clinical investigation.

[15]  Douglas W Mahoney,et al.  Agreement between self-report questionnaires and medical record data was substantial for diabetes, hypertension, myocardial infarction and stroke but not for heart failure. , 2004, Journal of clinical epidemiology.

[16]  Vilmundur Gudnason,et al.  C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. , 2004, The New England journal of medicine.

[17]  B. Jaber,et al.  Soluble Fas: a novel marker of inflammation in uremia. , 2003, Artificial organs.

[18]  I. Sirois,et al.  Soluble Fas: a novel predictor of atherosclerosis in dialysis patients. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[19]  J. Carcillo,et al.  sFas and sFas Ligand and Pediatric Sepsis-Induced Multiple Organ Failure Syndrome , 2002, Pediatric Research.

[20]  I. Sirois,et al.  Soluble Fas is a marker of coronary artery disease in patients with end-stage renal disease. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[21]  S. Haffner,et al.  The relation of body fat mass and distribution to markers of chronic inflammation , 2001, International Journal of Obesity.

[22]  W. Scherbaum,et al.  Soluble Fas is increased in hyperthyroidism independent of the underlying thyroid disease. , 2001, The Journal of clinical endocrinology and metabolism.

[23]  Y Ohno,et al.  Japan collaborative cohort study for evaluation of cancer risk sponsored by monbusho (JACC study). , 2001, Journal of epidemiology.

[24]  L. Owen-Schaub,et al.  Fas and Fas ligand interactions in malignant disease. , 2000, International journal of oncology.

[25]  S. Nagata,et al.  Apoptosis by Death Factor , 1997, Cell.

[26]  N. Unwin,et al.  Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .

[27]  Hong Chen,et al.  Elevated levels of serum soluble Fas are associated with organ and tissue damage in systemic lupus erythematosus among Chinese , 2005, Archives of Dermatological Research.

[28]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.